Bepradoic Acid API

Name	Bepradoic acid
Chinese name	贝哌度酸
Cas Number	-
Source	India
Qualifications	-/-/-/-/-

It was approved by the US FDA for marketing in February 2020. Bepidoxic acid can inhibit ATP citrate lyase and act upstream of HMG-CoA reductase in the cholesterol synthesis pathway. It can reduce endogenous cholesterol and reduce the increase in LDL-C levels by up-regulating LDL receptors, reducing muscle-related side effect. In addition to the monotherapy, Esperion Pharmaceuticals has also developed a fixed-dose combination of bepetrolic acid and ezetimibe. Clinical studies have shown that in patients treated with bepiduric acid and ezetimibe, low-density cholesterol levels were reduced by 36.2%, and high-sensitivity C-reactive protein (hs-CRP) was reduced by 35.1%, which was greater than that of ezetimibe monotherapy. Statins are currently the mainstream first-line drugs for lowering lipids. Unlike statins, bepiduric acid has not been observed in clinical trials such as myalgia and other toxic side effects. It is safe and well tolerated, and is suitable for patients who are intolerant to statins. Patients, which is expected to rewrite the existing lipid-lowering treatment pattern.

Hot Tags: bepradoic acid api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Cinacalcet Hydrochloride API, Vardenafil API, Fondaparinux API, Dapoxetine API, Salmeterol Xinafoate API, Tippyridine Hydrochloride API

• Previous: Dapsone API
• Next: Meloxicam API